| Autor: |
Rotstein, Jerome, Gilbert, Myron, Estrin, Irving |
| Zdroj: |
JAMA: Journal of the American Medical Association; May 1963, Vol. 184 Issue: 6 p517-518, 2p |
| Abstrakt: |
TO THE EDITOR: —Epsilon-aminocaproic acid (EACA), a 6-carbon amino acid which is completely excreted from the body in 5 hr, prevents the activation of the fibrinolytic system through the inhibition of the activator of plasminogen and through the direct inhibition of plasmin.1 Plasmin is a fibrinolysin which breaks down fibrin into small polypeptides which play a part in developing the clinical manifestations of inflammation, such as diapedesis and histamine release.2Thirty months ago, a group of 32 patients with progressive systemic sclerosis, as diagnosed by tissue biopsy, was given EACA as the sole therapeutic agent. The patients have been treated with the following regimen: 1 week of intravenous EACA therapy totaling 210 gm of the medication in 7 days, and thereafter maintenance on 32 gm of the oral liquid preparation each day.Six patients have not shown significant reversal of symptoms during therapy. The other 22 patients have |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
